Emerging role of $^{18}$F-fluorodeoxyglucose positron emission tomography for guiding management of hepatocellular carcinoma

Sang Mi Lee, Hong Soo Kim, Sangheun Lee, Jeong Won Lee

ORCID number: Sang Mi Lee (0000-0002-7943-3807); Hong Soo Kim (0000-0003-3966-9302); Sangheun Lee (0000-0002-7884-1622); Jeong Won Lee (0000-0002-2697-3578).

Author contributions: All authors equally contributed to this paper with conception and design of the study, literature review, drafting, revision, editing of the paper, and approval of the final version.

Supported by the Soonchunhyang University Research Fund.

Conflict-of-interest statement: No potential conflicts of interest.

Open-Access: This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Manuscript source: Invited manuscript

Revised: February 25, 2019
Accepted: March 1, 2019
Article in press: March 1, 2019

Abstract

Hepatocellular carcinoma (HCC) is one of major causes of cancer mortality worldwide. For decades, $^{18}$F-fluorodeoxyglucose (FDG) positron emission tomography (PET) has been widely used for staging, predicting prognosis, and detecting cancer recurrence in various types of malignant diseases. Due to low sensitivity of FDG PET for detecting intrahepatic HCC lesions, the clinical value of FDG PET in HCC patients has been limited. However, recent studies with diverse analytic methods have shown that FDG PET has promising role in aiding management of HCC patients. In this review, we will discuss the clinical role of FDG PET for staging, predicting prognosis, and evaluating treatment response in HCC. Further, we will focus on recent clinical studies regarding implication of volumetric FDG PET parameters, the significance of FDG uptake in HCC for selecting treatment and predicting treatment response, and the use of radiomics of FDG PET in HCC.

Key words: Hepatocellular carcinoma; Fluorodeoxyglucose F18; Positron emission tomography; Staging; Prognosis
Core tip: Because of low sensitivity, clinical use of \(^{18}\text{F}\)-fluorodeoxyglucose (FDG) positron emission tomography (PET) has been limited in patients with hepatocellular carcinoma (HCC). However, recent studies have shown clinical significance of FDG PET in various ways. The objective of this review is to provide an overview of the current literature regarding FDG PET in HCC and discuss emerging role of FDG PET in aiding management of HCC patients.

Citation: Lee SM, Kim HS, Lee S, Lee JW. Emerging role of \(^{18}\text{F}\)-fluorodeoxyglucose positron emission tomography for guiding management of hepatocellular carcinoma. World J Gastroenterol 2019; 25(11): 1289-1306
URL: https://www.wjgnet.com/1007-9327/full/v25/i11/1289.htm
DOI: https://dx.doi.org/10.3748/wjg.v25.i11.1289

INTRODUCTION

In 2018, approximately 841,000 new cases of liver cancer and 782,000 associated deaths occurred worldwide, with liver cancer being the second leading cause of cancer death for males[1]. Hepatocellular carcinoma (HCC) is the most common primary liver cancer, accounting for 75%-85% of cases of liver cancer[1]. HCC is well-known as a highly lethal cancer, showing similar numbers of new cases and cancer deaths[1,2]. Hepatitis B virus (HBV), hepatitis C virus (HCV), and alcohol intake are leading causes of HCC. In developed countries, obesity is an emerging risk factor for HCC[2,3]. The Barcelona Clinical Liver Cancer (BCLC) staging system, endorsed by the European Association for the Study of the Liver and the European Organization for Research and Treatment of Cancer (EASL-EORTC), has been considered as the standard staging system for HCC in clinical practice because it links tumor stage to treatment strategy and has been validated in various different clinical situations[4]. For HCC patients with stage 0 (single tumor < 2 cm) and stage A (single tumor > 2 cm or 3 tumor nodules < 3 cm), curative treatments including surgical resection, liver transplantation, and local ablation have been indicated[4]. For HCC patients with stage B (multinodular tumors), transarterial chemoembolization (TACE) is primarily recommended[4]. For HCC patients with stage C (tumors with portal vein invasion and/or extrahepatic spread), sorafenib is recommended as the first-line treatment[4].

\(^{18}\text{F}\)-fluorodeoxyglucose (FDG), a glucose analog, is carried into viable cells by glucose transporter and subsequently phosphorylated by hexokinase, which has the same metabolic pathway as glucose[5]. Therefore, FDG on positron emission tomography (PET) has been widely used as an imaging marker of glucose metabolism of normal organs and cancer tissue[6-8]. Since cancer cells show high rates of glycolysis, FDG uptake is increased in cancer tissue[5]. Thus, FDG PET has shown incremental value for diagnosing, staging, predicting prognosis, and restaging diverse kinds of malignant diseases[5,9-11]. In contrast, FDG uptake in HCC varies according to the differentiation of HCC lesion[12,13]. Earlier studies with FDG PET have shown a low diagnostic ability for detecting intrahepatic HCC lesions[13,14], leading to a preconception that FDG PET has limited clinical value in patients with HCC. Nevertheless, diverse attempts have been performed to establish clinical role of FDG PET in HCC and recent studies have shown encouraging results of FDG PET in aiding management of patients with HCC.

In this review, we first summarized characteristics of HCC cells related with FDG uptake and results of studies regarding diagnostic and prognostic values of FDG PET in HCC. We then overviewed recent studies that dealt with volumetric FDG PET parameters, the significance of FDG uptake in HCC for selecting treatment and predicting treatment response, and radiomics of FDG PET in patients with HCC.

RELATIONSHIP BETWEEN HCC CHARACTERISTICS AND FDG UPTAKE

Because cancer cells have higher glycolytic rates than normal cells, higher amounts of glucose transporter and hexokinase expression are observed in tumor cells, resulting...
in increased FDG uptake in cancer lesions\cite{15,16}. However, HCC cells show different expression patterns of proteins related to FDG uptake. HCC has lower level of glucose transporter-1 expression than cholangiocarcinoma and hepatic metastatic lesion\cite{17,18}. Furthermore, high expression of glucose-6-phosphatase which hydrolyzes FDG-6-phosphate to FDG can be transported out of the cell has been observed in HCC\cite{19}. These different expression patterns contribute to low accumulation of FDG uptake in HCC, thereby reducing sensitivity for detecting HCC lesions\cite{19,20}. Nevertheless, increased glucose transporter expression and hexokinase activity have been demonstrated in high-grade HCC which is positively correlated with FDG uptake\cite{21,22}. Therefore, diverse degrees of FDG uptake have been shown according to the histopathological grade of HCC\cite{12,14,20}. Well-differentiated HCC reveals tumor-to-normal tumor liver uptake ratio (TLR) of around 1.1, indicating difficulty of differentiating FDG uptake of well-differentiated HCC lesion from that of normal liver tissue\cite{22}. Meanwhile, TLR of poorly-differentiated HCC lesion is more than 2.0\cite{23}. A previous study has shown that, by using the degree of FDG accumulation in HCCs, FDG PET could differentiate poorly-differentiated type from well-differentiate type with a sensitivity of 84% and a specificity of 75%\cite{24}.

Recent studies have assessed the relationship between HCC characteristics and its FDG uptake at molecular level. Lee et al\cite{24} have compared gene expression profiles between HCCs with low FDG uptake and HCCs with high FDG uptake using surgical specimens of 10 HCC patients. In their study, HCCs with high FDG uptake demonstrated different gene expression profiles compared to those with low FDG uptake, showing increased expression of 11 genes particularly related to tumor cell adhesion, invasion, metastasis, anti-tumoral immunity, and chemotherapeutic response. They suggested that HCCs with high FDG uptake might have a more aggressive nature than those with low FDG uptake and that FDG uptake pattern of HCC could reflect potential of tumor progression and metastasis. Another recent study has evaluated the association between FDG uptake and expression of epithelial-mesenchymal transition markers in HCC\cite{24}. Epithelial-mesenchymal transition is the formation process of motile cells from immotile epithelial cells and is known to be involved in the formation of metastatic cancer cells\cite{24}. During epithelial-mesenchymal transition processes, expression levels of mesenchymal markers such as N-cadherin and vimentin increased, while expression of E-cadherin, an epithelial cell junction protein, is lost\cite{23,24}. The recent study demonstrated that, in HCCs with high FDG uptake, expression levels of N-cadherin and vimentin were up-regulated and the expression of E-cadherin was repressed\cite{24}. These significant associations between FDG uptake and expression of epithelial-mesenchymal transition-related proteins in HCC provides a basis for hypothesis that FDG PET might be useful for predicting the risk of extrahepatic metastasis in HCC patients\cite{21}.

**FDG PET IN STAGING HCC**

Due to reduced FDG uptake in low-grade HCCs, previous studies have consistently reported a low sensitivity of FDG PET for detecting primary HCC lesions, ranging from 36% to 70%\cite{21,23,24,25}. A previous study by Teefey et al\cite{23} even reported that FDG PET detected none of cancer lesions in nine patients with HCC who underwent imaging examinations for work-up of liver transplantation. Based on results of these studies, EASL-EORTC guidelines has mentioned that FDG PET scan is not accurate for early diagnosis of HCC\cite{26}. In contrast, FDG PET has shown promising results for detecting extrahepatic metastasis. Because poorly-differentiated HCCs tend to metastasize more frequently, a positive statistical correlation between FDG avidity of primary HCCs and tendency of extrahepatic metastasis has been shown, suggesting that metastatic HCC lesions would also have increased FDG uptake\cite{27}. Extrahepatic metastasis is an not unusual finding in HCC. During staging work-up of HCC, extrahepatic metastases have been found in up to 37% of patients, with the most frequent site of metastasis being the lung, followed by lymph node, bone, and adrenal gland\cite{28,29}. In previous studies, FDG PET has demonstrated high sensitivities of 77%-100% for detecting extrahepatic metastasis\cite{28,30,31}. FDG PET has also shown superior diagnostic ability for detecting bone metastasis compared to bone scintigraphy and incomparable diagnostic accuracy for detecting lymph node metastasis compared to conventional computed tomography (CT) scan\cite{31}. However, FDG PET has a low sensitivity of 20% for detecting pulmonary metastases of less than 1 cm\cite{31}. Therefore, the diagnostic accuracy of chest CT was superior to that of FDG PET for detecting pulmonary metastasis\cite{31}.

Clinical utility of imaging modality in staging malignant disease depends on whether the imaging examination can make further shift in cancer staging compared
FDG UPTAKE OF HCC AS A PREDICTOR FOR PROGNOSIS

Because FDG uptake of HCC is associated with tumor differentiation and aggressiveness, it is reasonable to assume that FDG uptake of HCC might have significant association with prognosis. Therefore, most studies on FDG PET in HCC patients have assessed the prognostic value of FDG PET for predicting clinical outcomes. These studies are summarized in Tables 2-4. In previous studies, visual analysis, maximum FDG uptake of tumor expressed as standardized uptake value (SUV), and TLR have been the most commonly used FDG PET parameters for evaluating FDG uptake of HCCs. Visual assessment and SUV are also commonly used as PET parameters in studies on other malignant diseases. TLR has been preferred in studies with HCC patients because TLR is known to correlate more closely with HCC doubling time and represent metabolic activities of HCCs more precisely than SUV.

In previous studies on HCC patients who underwent curative surgical resection (Table 2), FDG uptake of HCC showed significant association with tumor recurrence, especially early recurrence after surgery, and overall survival, demonstrating worse survival in patients with high FDG uptake. However, several studies have failed to show the relationship between FDG PET findings and clinical outcomes on multivariate analysis. A recent study by Kim et al. has retrospectively enrolled 226 patients with HBV-related HCC and evaluated the prognostic value of FDG PET findings. Results of that study revealed that, although positive FDG uptake of HCCs was significantly associated with overall survival, there was no significant difference in disease-free survival according to findings of FDG PET, suggesting that FDG PET could not predict the exact prognosis in patients with HBV-related HCC, because recurrence of HBV-related HCC also included intrahepatic metastasis or de novo recurrence. A retrospective multicenter study including 526 patients from nine Korean institutions has made a prognostic prediction model by combining alpha-fetoprotein (AFP)-des-gamma-carboxy prothrombin-tumor volume (ADV) score and FDG PET findings that are all available on staging work-up before surgical resection. The prognostic prediction model exhibited significant differences in tumor recurrence rates and overall survival rates according to ADV scores and PET findings, showing recurrence rate of 67.9% and survival rate of 70.6% in patients with high ADV score and hypermetabolic HCCs while the recurrence rate and survival rate in patients with low ADV score and isometabolic HCCs were 21.1% and 96.6%, respectively. The authors of that study suggested that, by using a combination of ADV scores and FDG PET findings, the risk of HCC recurrence could be reliably predicted.

In previous studies on HCC patients who underwent liver transplantation (Table 3), FDG PET findings consistently showed significant associations with recurrence-free survival and overall survival, demonstrating high recurrence rates after liver transplantation in patients with high FDG uptake. To select candidates for liver transplantation, the Milan criteria (a solitary tumor no more than 5 cm in diameter or 2 to 3 tumors no more than 3 cm in diameter) and the University of California San Francisco (UCSF) criteria (a solitary tumor up to 6.5 cm in diameter or up to 3 tumors
Table 1  Current literature evaluating the role of \(^{18}\)F-fluorodexoyglucose positron emission tomography in staging hepatocellular carcinoma

| First author | Year | No. of patients | Study design | Staging system | No. of patient with a change of stage by FDG PET | No. of patients with a change of treatment by FDG PET |
|--------------|------|----------------|--------------|----------------|-----------------------------------------------|-------------------------------------------------|
| Yoon et al\[34\] | 2007 | 87 | Not specified | TNM           | 4 patients (4.6%), 3 patients TNM Iva to IVb, 1 patient TNM III to IVa | Not specified                                      |
| Kawamura et al\[26\] | 2014 | 64 | Retrospective | BCLC          | 16 patients (25%), 6 patients BCLC 0 to C, 7 patients BCLC A to C, 5 patients BCLC B to C | 16 patients (25%)                                  |
| Cho et al\[35\] | 2014 | 457 | Retrospective | BCLC and TNM  | 7 patients (1.5%), 6 patients BCLC A to C, 1 patient BCLC B to C | 7 patients (1.5%)                                  |

FDG: \(^{18}\)F-fluorodexoyglucose; PET: Positron emission tomography; HCC: Hepatocellular carcinoma; BCLC: Barcelona Clinic Liver Cancer.

no more than 4.5 cm with a total diameter up to 8 cm) have been commonly used\[62,63\]. Therefore, most studies have compared the prognostic value of FDG PET with the conventional criteria or combined FDG PET findings with the conventional criteria to further stratify recurrence risk after liver transplantation\[51-58,61\]. In previous studies, patients beyond the Milan criteria, but, showing negative finding on FDG PET had clinical outcomes comparable to those within the Milan Criteria\[52,53,55,61\]. Furthermore, even if patients met the Milan criteria, higher recurrence rate was found in those with high FDG uptake of HCCs than that in those with low FDG uptake\[39,51\]. A previous study by Lee et al\[58\] has proposed new selection criteria with FDG PET finding and total tumor size (10 cm). The new criteria had similar area under the receiver operating characteristic curve value for predicting disease-free survival compared to the Milan criteria or the UCSF criteria\[58\]. Takada et al\[60\] have performed a retrospective multicenter study with 182 HCC patients who underwent living donor liver transplantation from 16 Japanese medical centers. In that study, FDG PET finding was found to be an independent predictive factor for tumor recurrence along with the Milan criteria and serum AFP level. Patients beyond the Milan criteria but with low serum AFP level and negative FDG PET finding (19%) had similar 5-year recurrence rate to those within the Milan criteria (6%). They also had significantly lower 5-year recurrence rate than those beyond Milan criteria with high serum AFP level and positive PET finding (53%). They suggested that FDG PET could provide additional information for making decisions regarding liver transplantation for HCC patients\[60\].

The prognostic value of FDG PET has also been assessed in HCC patients treated with palliative treatments including TACE, concurrent chemoradiotherapy (CCRT), radiotherapy, transarterial radioemolization (TARE), and sorafenib (Table 4)\[40,64-76\]. For patients treated with TACE, CCRT, or radiotherapy, previous studies showed longer progression-free survival and overall survival in patients with low FDG uptake of HCCs, indicating significant associations between FDG avidity of HCCs and clinical outcomes\[44-49,71,72\]. For patients treated with TARE using yttrium-90 (\(^{90}\)Y), contradictory results have been shown between studies. Previous studies have revealed longer progression-free survival and overall survival in patients with low FDG uptake of HCCs\[72,74\], including a recent prospective study with uniform patient cohort\[91\]. In contrast, one study showed no significant association between FDG avidity of HCCs and survival\[71\] and another study even showed better progression-free survival in patients with high FDG uptake\[80\]. This controversy could be due to the small number of enrolled patients with heterogeneous clinical conditions among studies and further larger studies are warranted. Only two studies have evaluated the prognostic value of FDG PET in patients treated with sorafenib monotherapy\[40,76\]. Both studies showed significantly better survival in patients with low FDG uptake of HCCs\[40,76\]. However, only a small number of patients are enrolled in both studies and concomitant local therapies are also commonly performed in patients with BCLC stage C. These might have limited analyses in these studies.

Recently, the Korean Society of Nuclear Medicine Clinical Trial Network (KSNM
| First author          | Year | No. of patients | Study design | PET parameter | Cut-off values of PET parameter | Findings                                                                 |
|----------------------|------|-----------------|--------------|---------------|---------------------------------|--------------------------------------------------------------------------|
| Hatano et al         | 2006 | 31              | Retrospective| TLR           | 2.0                             | TLR showed significant positive association with overall survival         |
| Ahn et al            | 2011 | 93              | Retrospective| SUV, TLR      | 4.0, 2.0                        | High SUV and TLR were predictors for early recurrence, but showed no statistical significance on multivariate analysis |
| Kitamura et al       | 2012 | 63              | Retrospective| TLR           | 2.0                             | TLR was an independent predictor for early recurrence                     |
| Han et al            | 2014 | 298             | Retrospective| SUV           | 3.5                             | SUV was an independent predictor for recurrence-free survival and overall survival |
| Baek et al           | 2015 | 54              | Retrospective| Tumor-to-muscle ratio | 6.36                          | Tumor-to-muscle ratio was associated with recurrence-free survival, but, no statistical significance on multivariate analysis |
| Cho et al            | 2017 | 56              | Retrospective| SUV           | 4.9                             | Recurrence rate was higher in patients with high SUV, but, no significant difference of disease-free survival and overall survival according to SUV |
| Hwang et al          | 2018 | 526             | Retrospective| Visual analysis| -                               | Combination of ADV score and PET finding can predict risk of early recurrence and survival |
| Kim et al            | 2018 | 226 HBV-related HCC | Retrospective| Visual analysis| -                               | Positive PET finding was associated with overall survival, but, not a predisposing factor for disease-free survival in HBV-related HCC patients |
| Lim et al            | 2018 | 78              | Prospective  | Visual analysis| -                               | Positive PET finding was an independent predictor for early recurrence |
| Yoh et al            | 2018 | 207             | Retrospective| TLR           | 2.0                             | Prognostic model incorporating ALBI grade and PET finding can predict the disease-free survival and overall survival |

FDG: $^{18}$F-fluorodeoxyglucose; PET: Positron emission tomography; HCC: Hepatocellular carcinoma; HBV: Hepatitis B virus; TLR: Tumor-to-non-tumor liver uptake ratio; SUV: Standardized uptake value; ADV: Alpha-fetoprotein-Des-gamma-carboxy prothrombin-tumor volume; ALBI: Albumin-bilirubin.

CTN) working group has performed a retrospective multicenter study to assess clinical role of FDG PET in HCC patients[77-80]. They retrospectively recruited 847
Table 3  Current literature evaluating the prognostic value of 18F-fluorodeoxyglucose positron emission tomography in hepatocellular carcinoma patients with liver transplantation

| First author      | Year | No. of patients | Study design | PET parameter | Cut-off values of PET parameter | Findings                                                                 |
|-------------------|------|-----------------|--------------|---------------|-------------------------------|--------------------------------------------------------------------------|
| Yang et al[51]    | 2006 | 38              | Retrospective| Visual analysis| -                             | Patients with negative PET findings had significantly higher recurrence-free survival than those with positive findings |
| Kornberg et al[52]| 2009 | 42              | Retrospective| Visual analysis| -                             | Patients with positive PET findings had significantly higher recurrence rate with lower recurrence-free survival than those with negative findings |
| Lee et al[39]     | 2009 | 59              | Retrospective| Tmax/Lmax      | 1.15                          | Tmax/Lmax was an independent predictor for recurrence-free survival       |
| Kornberg et al[53]| 2012 | 91              | Retrospective| Visual analysis| -                             | PET finding was an independent prognostic variable for recurrence-free survival, and positive PET status was the independent predictor of patient dropout from the waiting list of liver transplantation |
| Lee et al[54]     | 2013 | 191             | Retrospective| Visual analysis| -                             | Positive PET status was an independent prognostic factor for disease-free survival influencing early recurrence |
| Detry et al[55]   | 2015 | 27              | Retrospective| Tmax/Lmax      | 1.15                          | Tmax/Lmax independently predicted recurrence-free survival               |
| Hong et al[56]    | 2016 | 123             | Retrospective| TLR           | 1.10                          | Combination of serum AFP and PET finding predicted better disease-free survival than using the Milan criteria |
| Hsu et al[57]     | 2016 | 147             | Retrospective| SUV, TLR       | 4.8, 2.0                      | Combination of UCSF criteria and PET finding can predict the risk of recurrence |
| Lee et al[58]     | 2016 | 280             | Retrospective| Visual analysis| -                             | The criteria combined of FDG PET and total tumor size can predict disease-free survival and overall survival, and showed similar area under the ROC curve of the Milan and UCSF criteria |
Kornberg et al\[59\] 2017 116 Retrospective Visual analysis - Combining radiographic criteria with FDG PET finding can predict recurrence-free survival

Takada et al\[60\] 2017 182 Retrospective Visual analysis - PET positive status was an independent risk factor for recurrence-free survival

Ye et al\[61\] 2017 103 Retrospective Visual analysis - Patients beyond the Milan criteria with a negative PET finding had comparable recurrence-free survival in comparison with those within the Milan criteria

FDG: 18F-fluorodeoxyglucose; PET: Positron emission tomography; HCC: Hepatocellular carcinoma; Tmax/Lmax: Maximum FDG uptake of tumor-to-maximum FDG uptake of the normal liver ratio; TLR: Tumor-to-non-tumor liver uptake ratio; SUV: Standardized uptake value; AFP: Alpha-fetoprotein; UCSF: University of California San Francisco; ROC: Receiver operating characteristic.

patients with newly diagnosed HCC who underwent pretreatment FDG PET/CT from seven university hospitals at Korea and published several studies regarding the prognostic value of FDG PET\[77,78\]. One of their studies included 317 patients with BCLC stage 0 or A from the cohort and evaluated the predictive value of FDG PET for recurrence-free survival and overall survival\[77\]. They classified the 317 patients into two groups, a curative therapy cohort (patients who underwent surgical resection, liver transplantation, and local ablation) and a TACE cohort, and assessed the relationship between FDG PET findings and survival in each group. TLR was an independent predictor for both recurrence-free survival and overall survival in the curative therapy cohort. However, TLR failed to show association with survival in the TACE cohort. Considering that only patients who could not undergo curative therapy due to unsuitable HCC location or impaired liver function were included in the TACE cohort, underlying liver function rather than FDG uptake of HCC might have a significant association with survival\[77\].

Another study by KSNM CTN has evaluated prognostic value of FDG PET in 291 patients with BCLC stage C\[78\]. They classified patients into two groups; patients with intrahepatic metastasis and patients with extrahepatic metastasis. They showed that higher TLR was associated with extrahepatic metastasis and was an independent predictor for overall survival in both groups. Furthermore, patients with intrahepatic metastases but high TLR had a poor prognosis comparable to patients with extrahepatic metastases and low TLR, suggesting the prognostic significance of primary HCCs uptake irrespective of the extent of metastasis.

In addition to FDG uptake of primary HCC tumors, a recent study by Lee et al\[81\] has evaluated the prognostic value of FDG uptake of portal vein tumor thrombosis. HCC cells can spread to other segments of the liver and distant organs via portal vein; therefore, portal vein tumor thrombosis has a significant impact on the prognosis of HCC patients\[82-83\]. Lee et al\[81\] have enrolled 166 HCC patients with portal vein tumor thrombosis but no extrahepatic metastasis and compared the prognostic value of FDG uptake of portal vein tumor thrombosis with FDG uptake of primary tumor. Their results revealed that only FDG uptake of portal vein tumor thrombosis was an independent predictor for both progression-free survival and overall survival. They also found that patients with high FDG uptake of portal vein tumor thrombosis had worse survival than those with low FDG uptake, irrespective of the degree of FDG uptake of primary HCCs. Based on these results, they concluded that FDG uptake of portal vein tumor thrombosis rather than FDG uptake of primary tumor should be used to predict clinical outcomes in locally advanced HCC.

VOLUMETRIC PARAMETERS OF PET AND RECURRENCE PATTERN OF HCC
| First author | Year  | No. of patients | Study design | PET parameter | Cut-off values of PET parameter | Treatment | Findings |
|--------------|-------|----------------|--------------|---------------|---------------------------------|-----------|----------|
| Song et al[64] | 2012  | 83             | Retrospective | TLR           | 1.90                            | TACE      | Patients with low TLR ratios had significantly longer overall survival than those with high ratios, but, no significant difference of time-to-progression was shown between them |
| Song et al[65] | 2013  | 58             | Retrospective | TLR           | 1.70                            | TACE      | FDG PET can predict response to TACE and tumor progression |
| Ma et al[66]  | 2014  | 27             | Retrospective | ΔTSUVmax%     | 0.1                             | TACE      | ΔTSUVmax% can predict response to TACE and overall survival |
| Kim et al[67] | 2015  | 77             | Retrospective | TLR           | 1.83                            | TACE      | TLR was an independent predictor of overall survival and tumor progression |
| Kim et al[68] | 2011  | 107            | Retrospective | SUV           | 6.1                             | CCRT      | SUV was significantly associated with progression-free survival and overall survival, and patients with high SUV was more likely to have extrahepatic metastasis |
| Huang et al[69] | 2013 | 31            | Retrospective | SUV           | 3.2                             | SABR      | SUV was the significant prognostic indicator of disease control rate |
| Rhee et al[70] | 2017  | 228            | Retrospective | SUV, TLR      | 4.825,2.355                     | Radiotherapy | Low FDG uptake group had better treatment response, longer median progression-free and overall survival |
| Kucuk et al[71] | 2013 | 19            | Retrospective | Visual analysis | -                              | Radioembolization | High FDG uptake lesions unexpectedly had better progression-free survival rates |
| Sabet et al[72] | 2014 | 33            | Retrospective | Visual analysis | -                              | Radioembolization | Findings on pre-therapeutic PET and relative changes of FDG uptake on post-therapeutic PET independently predict overall survival |
FDG: 18F-fluorodeoxyglucose; PET: Positron emission tomography; HCC: Hepatocellular carcinoma; TLR: Tumor-to-non-tumor liver uptake ratio; ΔTSUVmax%: Relative changes of maximum FDG uptake of tumor between pre-therapeutic and post-therapeutic FDG PET scans; SUV: Standardized uptake value; TACE: Transarterial chemoembolization; CCRT: Concurrent chemoradiotherapy; SABR: Stereotactic ablative radiotherapy; AFP: Alpha-fetoprotein.

In recent decades, volumetric PET indices such as metabolic tumor volume (MTV) and total lesion glycolysis (TLG) have been considered as promising PET parameters that can accurately reflect the metabolic burden of malignant lesion[84-86]. SUV and TLR represent only the highest metabolic activity of cancer lesion. On the other hand, MTV is defined as tumor tissue volume that has FDG uptake beyond the intensity of FDG uptake of normal tissue; thus, it can reflect tumor extent[85-87]. TLG is the product of MTV and mean FDG uptake of tumor, which combines both metabolic and volumetric information of the tumor[84,86]. A number of studies have demonstrated that MTV and TLG have higher predictive values for survival than SUV in various malignant diseases during the last two decades[84-89]. However, in HCC patients, clinical study that calculated MTV and assessed the prognostic value of MTV was first published in 2015[90]. Since then, only a few studies have evaluated the clinical implication of volumetric PET parameters[91-93].

To measure MTV of cancer lesion, two processes should be performed: delineating tumor lesion from surrounding normal tissue and determining threshold SUV to identify metabolically active tumor volume[90]. Due to heterogeneous and diverse degrees of FDG uptake in HCC and relatively high FDG uptake in normal liver tissue, it is difficult to perform both processes in HCC, thus hindering attempts to measure volumetric PET parameters[90]. Lee et al[90] have proposed a novel method using intensity-volume histogram to measure MTV of HCCs that can surpass these limitations. They drew regions of interest over HCC lesion and normal liver tissue and prepared intensity-volume histogram (a plot of volume of a given structure as a function of the SUV) of the HCC lesion and normal liver tissue (Figure 1). Using such intensity-volume histograms of HCC and normal liver tissue, the sum of tumor voxels with higher FDG uptake than normal liver tissue could be calculated for each patient. They calculated MTV2SD (defined as the sum of the tumor voxels over the SUV of the 97.5th percentile of the normal liver tissue voxels) from 59 HCC patients without extrahepatic metastasis. On survival analysis of their study, MTV2SD has more significant prognostic value for predicting progression-free survival and overall survival than TLR.

After publishing the first study with MTV in HCC, authors of the study have tried

| Study | Year | Study Design | imaging analyses | SUV | Radioembolization | Prognostic Factors | Other Details |
|-------|------|--------------|-----------------|-----|-------------------|-------------------|--------------|
| Soydal et al[73] | 2015 | Retrospective | Visual analysis, SUV | Not specified | Radioembolization | Age, serum AFP level, and tumor size were significantly associated with survival, but, SUV showed no significant association | |
| Abuodeh et al[74] | 2016 | Retrospective | Visual analysis | - | Radioembolization | FDG avidity independently predicts local liver control, distant liver control, and progression-free survival | |
| Jreige et al[75] | 2017 | Prospective | SUV, TLR | 5.0,2.0 | Radioembolization | Both SUV and TLR were predictive markers of overall survival | |
| Lee et al[76] | 2011 | Retrospective | SUV | 5.0 | Sorafenib | SUV was an independent prognostic factor for overall survival | |
| Sung et al[40] | 2018 | Retrospective | TLR | 2.9 | Sorafenib | TLR was a significant predictor for progression-free survival and overall survival | |
Figure 1  An example of the method for measuring metabolic tumor volume based on intensity-volume histogram from reference\(^88\) with permission. Maximal intensity projection (A) and transaxial image (C) of \(^{18}\)F-fluorodeoxyglucose (FDG) positron emission tomography (PET) and contrast-enhanced computed tomography image (B) showed a single hepatocellular carcinoma (HCC) with moderately increased FDG uptake. Regions of interest of HCC (red) and normal liver tissue (blue) are manually drawn on transaxial PET images (D). Cumulative intensity-volume histogram plots for HCC (red) and normal liver tissue (blue) are calculated from regions of interest. Standardized uptake value of the 97.5\(^{th}\) percentile of the voxels of the normal liver tissue was 2.7 (blue box) and the fraction of the tumor volume with ≥ 2.7 was 71.9\% (black box). As the total tumor volume was 27.9 cm\(^3\) (red box), sum of the tumor voxels over the standardized uptake value of the 97.5\(^{th}\) percentile of the normal liver tissue voxels of the patient was 20.1 cm\(^3\). HCC: Hepatocellular carcinoma; SUV: Standardized uptake value.

to assess the clinical value of volumetric PET parameters for predicting recurrence pattern of HCC\(^{[92,93]}\). In HCC patients, extrahepatic metastasis after curative surgical resection is known to be associated with poor prognosis due to limited therapeutic option\(^{[42,92]}\). Furthermore, early recurrence with an interval of less than one year after operation is also known to be a significant indicator for worse survival which is comparable to the survival of patients with extrahepatic metastasis\(^{[47,93,94]}\). In previous studies, tumor factors associated with tumor aggressiveness including tumor stage, size, and grade have been found to be significant predictors for both extrahepatic and early recurrences\(^{[47,93,95,96]}\). FDG uptake of HCC is also related to tumor grade and aggressiveness, therefore, SUV and TLR of HCCs have also been shown to be associated with the risk of extrahepatic and early recurrences\(^{[42,45,47,97]}\). Considering that volumetric PET parameters can more precisely reflect metabolic characteristics and burden of cancer lesions than FDG uptake intensity\(^{[86,89]}\), volumetric PET parameters of HCC can have more significant association with recurrence patterns of HCC than...
SUV or TLR. In two recent studies on the relationship between volumetric PET parameters and recurrence pattern of HCC, the authors have measured MTV and TLG of HCCs using SUV of the 97.5th percentile of the normal liver tissue as threshold SUV and demonstrated that both MTV and TLG have superior prognostic value for predicting both extrahepatic recurrence and early intrahepatic recurrence than TLR in HCC patients after curative surgical resection[92,93]. On the other hand, late intrahepatic recurrence with an interval of more than 1 year after surgery was associated with HCV positivity and serum albumin level, while none of volumetric PET parameters could predict the risk of late intrahepatic recurrence[91]. These results indicate that the risk of both extrahepatic and early intrahepatic recurrences is associated with metabolic tumor burden, while the risk of late intrahepatic recurrence is related to underlying liver function and multicentric tumor formation tendency[91]. Authors of these studies have suggested that volumetric PET parameters of HCC could be used to predict the recurrence pattern and to select patients who might show poor survival after curative surgical resection[92,93].

Kim et al[100] have calculated volumetric PET indices and evaluated their prognostic values in 110 HCC patients who underwent liver transplantation. Different from the method used in the study by Lee et al[90], they calculated uptake ratio between the maximum SUV of HCCs and background tissue, inferior vena cava (TBR_{intra}) or normal liver tissue (TBR_{NL}), and used TBR_{intra} of 2.0 and TBR_{NL} of 1.5 as threshold values for measuring MTV. MTV_{IVC} and MTV_{NL} (defined as the sum of the tumor voxels which had TBR_{intra} of more than 2.0 and TBR_{NL} of more than 1.5) were measured. With MTV and mean value of TBR, uptake-volume product (UVP) was calculated for each background tissue. Results of their study revealed that both TBR_{intra} and UVP_{intra} were independent predictors for recurrence-free survival. The authors suggested that inferior vena cava might be a more reliable background tissue than the normal liver in measuring MTV. They have also suggested that volumetric parameters as well as metabolic activity of HCCs are effective predictors of recurrence after liver transplantation[91].

**USING FDG PET FOR SELECTING TREATMENT OF HCC**

Increased FDG uptake in HCCs reflects aggressive biological activity of tumor and is associated with poor survival[18,19,78]. Therefore, patients with high FDG uptake of HCCs might have poor response to treatment. Previous studies on patients treated with TACE have shown that patients with high FDG uptake have poor response to treatment[101,102]. Furthermore, in HCC patients with high FDG uptake, major hepatectomy that can minimize the possibility of residual tumor rather than minor hepatectomy should be selected to obtain survival benefit[90]. However, in studies on HCC patients treated with external beam radiotherapy, paradoxical relationship between FDG uptake of HCC and treatment response has been shown[92,93]. Kim et al[100] have retrospectively enrolled 35 HCC patients with TNM stage III-IV who underwent FDG PET and subsequent radiotherapy with concurrent chemotherapy or TACE. They showed that patients having HCCs of SUV ≥ 2.5 (80%; 16 out of 20 patients) had significantly higher objective response rate to radiotherapy than those with SUV < 2.5 (40%; 6 out of 15 patients). Choi et al[101] have retrospectively reviewed 45 metastatic bone lesions in 22 HCC patients treated with radiotherapy. They also revealed significantly better infield progression-free survival and infield event-free survival in tumors with SUV of ≥ 3.0 compared to those in tumors with SUV of < 3.0 (1-year progression-free survival, 88% vs 34%; 1-year event-free survival, 82% vs 52%). Another retrospective study by Jo et al[102] has investigated the predictive value of FDG uptake of HCC in 36 HCC patients treated with radiotherapy. In that study, patient group with high SUV (≥ 5.1) showed significantly higher objective tumor response (63.6% vs 36.4%) than patient group with low SUV (< 5.1). In spite of high tumor response, patient group with high SUV had worse overall survival mainly due to the occurrence of distant metastasis. Authors of these studies have explained this paradoxical relationship by radiosensitivity of highly proliferating tumor[100,102]. In a previous study, FDG uptake of HCCs has shown a positive association with tumor doubling time[90]. Because rapidly proliferating tumors are radiosensitive, HCCs with high FDG uptake are considered to have better response to radiotherapy than those with low uptake[101,102]. However, HCCs with high FDG uptake also have high risk for early recurrence and distant metastasis[92,93]. Therefore, viable tumor cells in residual lesions after radiotherapy could spread more rapidly and more frequently to extrahepatic organs, resulting in worse overall survival[102].

Results of these studies on radiotherapy have indicated that HCCs might show different responses to treatment according to the degree of FDG uptake of HCC. In
this respect, a recent study reported by KSNM CTN working group has demonstrated interesting results\(^7\). The study retrospectively enrolled 214 intermediate-to-advanced stage patients without extrahepatic metastasis who underwent CCRT or TACE as an initial treatment from a cohort of 847 HCC patients from seven hospitals. Authors of the study have classified these enrolled patients into two patient groups according to TLR of HCCs (patient groups with TLR > 2.0 and ≤ 2.0) and compared clinical outcomes between patients treated with CCRT and TACE for each patient group. In patient group with TLR > 2.0, patients treated with CCRT demonstrated significantly longer progression-free survival and overall survival than those treated with TACE. Meanwhile, for patient group with TLR ≤ 2.0, there were no significant differences in progression-free survival or overall survival between patients treated with CCRT and those treated with TACE. The authors suggested that, for patients with high FDG uptake, multimodality treatment including radiotherapy could be more effective in tumor control while HCCs with low FDG uptake seemed to be less affected by the treatment modality. Considering that HCCs with low and high FDG uptake have different tumor characteristics, genetic disposition, and recurrence pattern\(^18,19,21,93\), different treatment strategy might be needed according to findings of FDG PET in HCC patients. However, as the study by KSNM CTN working group\(^7\) was retrospectively performed, further prospective study is needed to validate the role of FDG PET in selecting treatment modality.

RADIOMICS OF FDG PET IN HCC

Currently, the concept of radiomics has been widespread in the field of oncology\(^109\). Radiomics is defined as high-throughput extraction of a large number of imaging features that can comprehensively quantify tumor phenotypes\(^104,105\). Textural features of cancer tissue on medical images are associated with genomic and proteomic expression patterns of cancer cells and many studies have revealed that radiomics signature made of textural features can independently predict prognosis in diverse cancers including head and neck cancer, lung cancer, breast cancer, and esophageal cancer\(^105,106,107\). However, in HCC, only a single study by Blanc-Durand et al\(^107\) has evaluated the prognostic value of textural features of HCC. In radiomics study of FDG PET, image preprocessing including the process of delineation and segmentation of tumor lesion is essential for textural analysis of PET images\(^105,108\). Considering that HCC lesions have heterogeneous and variable FDG uptake, it is difficult to delineate HCC lesions from normal liver tissue accurately as shown in aforementioned section with volumetric PET parameters\(^90\). This might act as the main hurdle to perform textural analysis in FDG PET images of HCC. Blanc-Durand et al\(^107\) have retrospectively enrolled 47 HCC patients who underwent pretreatment FDG PET and subsequent transarterial radioembolization using \(^90\)Y. Using PET images of whole liver including both tumor and non-tumoral liver for textural analysis, they extracted 108 textural features from these images. They claimed that, by introducing whole-liver in the radiomics model, both hepatic function and HCC biology could be integrated into one system. With mainly using two textural features, strength (a textural feature describing pattern perceivability, its value is high when intensity pattern is easily defined and visible) and variance (a textural feature describing a deviation from the mean), predictive radiomics scoring systems for progression-free survival and overall survival were generated. On multivariate survival analysis, these radiomics scoring systems turned out to be independent negative predictors for both progression-free survival and overall survival. Moreover, prognostic values of radiomics scoring systems did not differ even after stratification by BCLC staging and tumor size. The authors suggested that whole-liver radiomics approach representing a balance between normal liver tissue and tumor burden could provide prognostic information for HCC patients. However, further studies with more patients are warranted to validate the methodology and results of their study.

CONCLUSION

FDG PET is a non-invasive imaging method that can evaluate biological activity of HCC. Although FDG PET has been considered to have low sensitivity for detecting HCCs, it can detect unexpected extrahepatic metastasis with incremental prognostic value for predicting survival. Furthermore, recent studies have demonstrated encouraging results of FDG PET for predicting recurrence pattern and aiding the selection of treatment for HCC. With development of new analytic methods of FDG PET images such as volumetric and textural analyses, clinical use of FDG PET in HCC
patients would be continuously evolving. FDG PET should be considered as an imaging biomarker that can provide information for selecting management strategies in HCC patients rather than a simple diagnostic imaging modality with a limited sensitivity.

REFERENCES

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394-424 [PMID: 30207593 DOI: 10.3322/caac.21492]

2. Yang JD, Roberts LR. Hepatocellular carcinoma: A global view. Nat Rev Gastroenterol Hepatol 2010; 7: 448-458 [PMID: 20626345 DOI: 10.1038/nrgastro.2010.100]

3. Marenco A, Rosso C, Bugianesi E. Liver Cancer: Connections with Obesity, Fatty Liver, and Cirrhosis. Am J Gastroenterol 2016; 113: 103-117 [PMID: 26473416 DOI: 10.1111/ajg.00934-013832]

4. European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-943 [PMID: 22424438 DOI: 10.1016/j.jhep.2011.12.001]

5. Kelloff GJ, Hoffman JM, Johnson B, Scher HI, Siegel BA, Cheng EY, Cheson BD, O'Shaughnessy J, Guyton KZ, Mankoff DA, Shankar L, Larson SM, SimGAN CC, Schlisky RL, Sullivan DC. Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res 2005; 11: 2795-2808 [PMID: 15837727 DOI: 10.1158/1078-0432.ccr-04-2626]

6. Lee JW, Lee MS, Chung JK, Son MW, Cho YS, Lee SM. Clinical implication of FDG uptake of bone marrow on PET/CT in gastric cancer patients with surgical resection. World J Gastroenterol 2017; 23: 2385-2395 [PMID: 28428718 DOI: 10.3748/wjg.v23.i13.2385]

7. Lee JW, Lee SM, Chung YA. Prognostic value of CT attenuation and FDG uptake of adipose tissue in patients with pancreatic adenocarcinoma. Clin Radiol 2018; 73: 1050.e1-1050.e10 [PMID: 30077337 DOI: 10.1016/j.crad.2018.07.094]

8. Pourhassan Shamchi S, Khosravi M, Taghvaii R, Zirakzian Zadeh M, Paydary K, Emamzadehfard S, Werner TJ, Haflund-Carlson PF, Alavi A. Normal patterns of regional brain (18)F-FDG uptake in normal aging. Hell J Nucl Med 2018; 21: 175-180 [PMID: 30411727 DOI: 10.1067/j.sjnm.2018.09.0092]

9. Cheng G, Huang H. Prognostic Value of (18)F-Fluorodeoxyglucose PET/Computed Tomography in Non-Small-Cell Lung Cancer. PET Clin 2018; 13: 59-72 [PMID: 29157336 DOI: 10.1016/j.cetp.2017.08.006]

10. Diao W, Tian F, Jia Z. The prognostic value of SUVmax measuring on primary lesion and ALN by (18)F-FDG PET or PET/CT in patients with breast cancer. Eur J Radiol 2018; 105: 1-7 [PMID: 30012764 DOI: 10.1016/j.ejrad.2018.05.014]

11. Lee Y, Yoo IR, Boo SH, Kim H, Park HL, Hyun O J. The Role of F-18 F-FDG PET/CT in Intrahepatic Cholangiocarcinoma. Nucl Med Mol Imaging 2017; 51: 69-78 [PMID: 28250860 DOI: 10.1007/s13139-016-0440-y]

12. Khan MA, Combs CS, Brutn EM, Lowe VJ, Wolverson MK, Solomon H, Collins BT, Di Bisegamie AM. Positron emission tomography scanning in the evaluation of hepatic cellular carcinoma. J Hepatol 2000; 32: 792-797 [PMID: 10845660 DOI: 10.1016/S0168-8278(00)00824-2]

13. Trojan J, Schroeder O, Raedle J, Baum RP, Herrmann G, Jacobi V, Zeuzem S. Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma. Am J Gastroenterol 1999; 94: 3314-3319 [PMID: 10366736 DOI: 10.1111/j.1572-0241.1999.01544.x]

14. Delbeke D, Martin WH, Sandler MP, Chapman WC, Wright JK, Pinson CW. Evaluation of benign vs malignant hepatic lesions with positron emission tomography. Arch Surg 1998; 133: 510-5; discussion 515-6 [PMID: 9605913 DOI: 10.1016/10.1016/s0003-9892(98)00225-1]

15. Ong LC, Jin Y, Song IC, Yu S, Zhang K, Chow PK. [2-18F]-2-deoxy-D-glucose (FDG) uptake in human tumor cells is related to the expression of GLUT-1 and hexokinase II. Acta Radiol 2008; 49: 1145-1153 [PMID: 18979289 DOI: 10.1038/anr.2008.100]

16. Zhao S, Kuge Y, Mochizuki T, Takahashi T, Nakada K, Sato M, Takei T, Tamaki N. Biologic correlates of intratumoral heterogeneity in 18F-FDG distribution with regional expression of glucose transporters and hexokinase-II in experimental tumor. Acta Radiol 2008; 49: 1145-1153 [PMID: 18979289 DOI: 10.1038/anr.2008.100]

17. Zimmerman RL, Burke M, Young NA, Solomonides CC, Bibbo M. Diagnostic utility of Glut-1 and CA 15-3 in discriminating adenocarcinoma from hepatocellular carcinoma in liver tumors biopsied by fine-needle aspiration. Cancer 2002; 96: 53-57 [PMID: 11836704 DOI: 10.1121/cncr.10.309]

18. Lee JD, Yang WI, Park YN, Kim KS, Choi JS, Yun M, Ko D, Kim TS, Cho AE, Kim HM, Han KH, Im SS, Ahn YH, Choi CW, Park JH. Different glucose uptake and glycolytic mechanisms between hepatocellular carcinoma and intrahepatic mass-forming cholangiocarcinoma with increased (18)F-FDG uptake. J Nucl Med 2005; 46: 1753-1759 [PMID: 16204727]

19. Torizuka T, Tamaki N, Inokuma T, Magata Y, Yaseyama Y, Yonekura Y, Tanaka A, Yamaoke Y, Yamamoto K, Konishi J. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med 1995; 36: 1811-1817 [PMID: 7562049]

20. Ho CL, Yu SC, Yeung DW. 11C-acetate PET imaging in hepatocellular carcinoma and other liver masses. J Nucl Med 2003; 44: 213-221 [PMID: 12571212]

21. Lee M, Jeon JY, Neugent ML, Kim JW, Yun M. 18F-Fluorodeoxyglucose uptake on positron emission tomography/computed tomography is associated with metastasis and epithelial-mesenchymal transition in hepatocellular carcinoma. Clin Exp Metastasis 2017; 34: 251-260 [PMID: 28429180 DOI: 10.1007/s10585-017-9847-9]

22. Ferda F, Ferdow E, Baxa J, Kreuzberg B, Daum O, Trieka Y, Skalický T. The role of 18F-FDG accumulation and arterial enhancement as biomarkers in the assessment of typing, grading and staging of hepatocellular carcinoma using 18F-FDG-PET/CT with integrated dual-phase CT angiography. Anticancer Res 2015; 35: 2241-2246 [PMID: 26382085]

23. Zeisberg M, Neilson EG. Biomarkers for epithelial-mesenchymal transitions. J Clin Invest 2009; 119: 1429-1437 [PMID: 19487819 DOI: 10.1172/JCI36183]

24. Wudel LJ, Delbeke D, Morris D, Rice M, Washington MK, Shyr Y, Pinson CW, Chapman WC. The role of [(18)F]fluorodeoxyglucose positron emission tomography imaging in the evaluation of hepatocellular carcinoma. Am Surg 2003; 69: 117-24; discussion 124-6 [PMID: 12641351]

Lee SM et al. FDG PET in HCC
Ijichi H, Shirahke K, Takeotomi A, Yoshizumi T, Ikemaru T, Mano Y, Aishima S, Abe K, Honda H, Maehara Y. Clinical usefulness of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography for patients with primary liver cancer with special reference to rare histological types, hepatocellular carcinoma with sarcomatous change and combined hepatocellular and cholangiocarcinoma. Hepatol Res 2013; 43: 481-487 [PMID: 23145869 DOI: 10.1111/j.1872-034X.2012.01107.x]

Kawamura E, Shiomi S, Kotonai K, Kawai J, Hagihara A, Fujii H, Uchida-Kobayashi S, Iwai S, Morikawa H, Enomoto M, Murakami Y, Tamori A, Kawada N. Positioning of 18F-fluorodeoxyglucose-positron emission tomography imaging in the management algorithm of hepatocellular carcinoma. J Gastroenterol Hepatol 2014; 29: 1722-1731 [PMID: 24370667 DOI: 10.1111/j.1440-1746.2014.06269.x]

Teefey SA, Hildebolt CC, Dehdashti F, Siegel BA, Peters MG, Heiken JP, Brown JJ, McFarland EG, Middleton WD, Balfé DM, Ritter JH. Detection of primary hepatic malignancy in liver transplant candidates: prospective comparison of CT, MR imaging, US, and PET. Radiology 2003; 226: 533-542 [PMID: 12263151 DOI: 10.1148/radiol.2262011990]

Ho CL, Chen S, Yeung DW, Cheng TK. Dual-tracer PET/CT imaging in evaluation of metastatic hepatocellular carcinoma. J Nucl Med 2007; 48: 902-909 [PMID: 17504862 DOI: 10.2967/jnumed.106.056673]

Kotayl S, Oliver JH, Peterson MS, Ferris JV, Carr BS, Baron RL. Extrahepatic metastases of hepatocellular carcinoma. Radiology 2006; 216: 698-703 [PMID: 16966697 DOI: 10.1148/radiology.216.3.r06eu24698]

Uka K, Aikata H, Takaki S, Shirakawa H, Jeong SC, Yamashina K, Hiramatsu A, Kodama H, Takahashi S, Chayama K. Clinical features and prognosis of patients with extrahepatic metastases from hepatocellular carcinoma. World J Gastroenterol 2007; 13: 414-420 [PMID: 17230611 DOI: 10.3748/wjg.v13.i3.414]

Lee JH, Jang PY, Jeong SW, Lee SH, Kim SI, Cha SW, Kim YS, Cho YD, Kim HS, Kim BS, Jun SY, Choi DL. Diagnostic value for extrahepatic metastases of hepatocellular carcinoma in positron emission tomography/computed tomography scan. World J Gastroenterol 2012; 18: 2979-2987 [PMID: 22736922 DOI: 10.3748/wjg.v18.i23.2979]

Sugiyama M, Sakahara H, Torizuka T, Kanno T, Nakamura F, Futatsubashi M, Nakamara S. 18F-FDG PET in the detection of extrahepatic metastases from hepatocellular carcinoma. J Gastroenterol 2004; 39: 961-968 [PMID: 15549440 DOI: 10.1007/s00255-004-1427-5]

Park JW, Kim JH, Kim SK, Kang KW, Park KW, Choi JI, Lee WJ, Kim CM, Nam BH. A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma. J Nucl Med 2008; 49: 1912-1921 [PMID: 18997056 DOI: 10.2967/jnumed.108.058587]

Yoon KT, Kim JK, Kim DY, Ahn SH, Lee JD, Yun M, Rha SY, Chon CY, Han KH. Role of 18F-fluorodeoxyglucose positron emission tomography in detecting extrahepatic metastasis in pretreatment staging of hepatocellular carcinoma. Oncology 2007; 72 Suppl 1: 104-110 [PMID: 18087100 DOI: 10.1515/0001171175]

Cho Y, Lee DH, Lee YB, Lee M, Yoo JJ, Choi WM, Cho YV, Paeng JC, Kang KW, Chung JK, Yu SJ, Lee JH, Yoon JH, Lee HS, Kim YJ. Does 18F-FDG positron emission tomography-computed tomography have a role in initial staging of hepatocellular carcinoma? PLoS One 2014; 9: e105679 [PMID: 25153834 DOI: 10.1371/journal.pone.0105679]

Lee JW, Lee SM, Lee MS, Shin HC. Role of ‘F-FDG PET/CT in the prediction of gastric cancer recurrence after curative surgical resection. Eur J Nucl Med Mol Imaging 2012; 39: 1425-1434 [PMID: 22673973 DOI: 10.1007/s00259-012-2164-2]

Lee JW, Na JO, Kang DY, Lee SY, Lee SM. Prognostic Significance of FDG Uptake of Bone Marrow on PET/CT in Patients With Non-Small-Cell Lung Cancer After Curative Surgical Resection. Clin Lung Cancer 2017; 18: 198-206 [PMID: 27495385 DOI: 10.1016/j.clu.2016.07.001]

Shiomi T, Nishiguchi S, Ishizuka Y, Iwata Y, Sasaki N, Tamori A, Haba Y, Tani T, Kubo S, Ochi H. Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose for predicting outcome in patients with hepatocellular carcinoma. Am J Gastroenterol 2001; 96: 1877-1880 [PMID: 11419843 DOI: 10.1111/j.1572-0241.2001.03888.x]

Lee JW, Paeng JC, Kang KW, Kwon IH, Suh KS, Chung JK, Lee MC, Lee DS. Prediction of tumor recurrence by 18F-FDG PET in liver transplantation for hepatocellular carcinoma. J Nucl Med 2009; 50: 682-687 [PMID: 19372474 DOI: 10.2967/jnumed.108.060574]

Sung PS, Park HL, Yang K, Hwang S, Song MJ, Jung JW, Choi JY, Yoon SK, Yoo IR, Bae SH. 18F-fluorodeoxyglucose uptake of hepatocellular carcinoma as a prognostic predictor in patients with sorafenib treatment. Eur J Nucl Med Mol Imaging 2018; 45: 384-391 [PMID: 29124280 DOI: 10.1007/s00259-017-3871-5]

Hatano E, Ikai I, Hegashi T, Teramaki S, Torizuka T, Saga T, Fujii H, Shimahara Y. Preoperative positron emission tomography with fluorine-18-fluorodeoxyglucose is predictive of prognosis in patients with hepatocellular carcinoma after resection. World J Surg 2006; 30: 1736-1741 [PMID: 16850145 DOI: 10.1007/s00268-005-0791-5]

Kitamura K, Hatano E, Hegashi T, Seo S, Nakamoto Y, Yamanaka K, Iida T, Taura K, Yasukuchi K, Uemoto S. Preoperative FDG-PET predicts recurrence patterns in hepatocellular carcinoma. Ann Surg Oncol 2012; 19: 156-162 [PMID: 21850564 DOI: 10.1245/s10434-011-1990-y]

Hase H, Kim DG, Na GH, Kim EY, Lee SH, Hong TH, You YK. Evaluation of prognostic factors on recurrence after curative resections for hepatocellular carcinoma. World J Gastroenterol 2014; 20: 17132-17140 [PMID: 25493027 DOI: 10.3748/wjg.v20.i45.17132]

Cho KJ, Choi NK, Shin MH, Chong AR. Clinical usefulness of FDG-PET in patients with hepatocellular carcinoma undergoing surgical resection. Ann Hepatobiliary Pancreat Surg 2017; 21: 94-198 [PMID: 29264581 DOI: 10.14710/ahps.2017.21.4.190]

Lim C, Salloum C, Chalaye J, Lafet E, Costentin CE, Osseis M, Itti E, Feray C, Arouldy K. 18F-18F-FDG PET/CT predicts microvascular invasion and early recurrence after liver resection for hepatocellular carcinoma: A prospective observational study. HPB (Oxford) 2018 [PMID: 30401520 DOI: 10.1111/hpb.2018.10.007]

Toshisuke T, Seo S, Ogiwa S, Kawai T, Okuda Y, Ishii T, Taura K, Hegashi T, Nakamoto Y, Hatano E, Kaito T, Uemoto S. Proposal of a New Preoperative Prognostic Model for Solitary Hepatocellular Carcinoma Incorporating [18F]-FDG-PET Imaging with the ALBI Grade. Ann Surg Oncol 2018; 25: 542-549 [PMID: 29168098 DOI: 10.1245/s10434-017-6262-z]

Ahn SG, Kim SH, Jeon TJ, Cho HJ, Choi SB, Yun MJ, Lee JD, Kim KS. The role of preoperative [18F]fluorodeoxyglucose positron emission tomography in predicting early recurrence after curative resection of hepatocellular carcinomas. J Gastrointest Surg 2011; 15: 2044-2052 [PMID: 21908962 DOI: 10.1007/s11605-010-1478-x]
Lee SM et al. FDG PET in HCC

10.1007/s11605-011-1660-1

Baek YH, Lee SW, Jeong YJ, Jeong JS, Roh YH, Han SY. Tumor-to-muscle ratio of 18F-FDG PET for predicting histologic features and recurrence of HCC. *Hepatogastroenterology* 2015; 62: 383-388 [PMID: 25916069]

Kim JM, Kwon CHD, Joo JW, Sim DH, Choi GS, Paik SW. Prognosis of preoperative positron emission tomography uptake in hepatocyte patients. *Ann Surg Treat Res* 2018; 94: 183-189 [PMID: 29629352 DOI: 10.4174/astr.2018.94.4.183]

Hwang S, Joo JW, Wang HJ, Kim DG, Kim KS, Suh KS, Kim SH, Yu HC, Cho CK, Lee YJ, Kim KH, Kim JM, Kim BW, Lee SG. Prognostic Prediction Models for Rejection of Large Hepatocellular Carcinoma: A Korean Multicenter Study. *World J Surg* 2018; 42: 2579-2591 [PMID: 29340726 DOI: 10.1007/s00268-018-4486-2]

Yang SH, Suh KS, Lee HW, Cho EH, Cho JY, Cho YB, Yi NJ, Lee KU. The role of (18)F-FDG-PET imaging for the selection of liver transplantation candidates among hepatocellular carcinoma patients. *Liver Transpl* 2006; 12: 1655-1660 [PMID: 16966489 DOI: 10.1002/lt.20601]

Kornberg A, Freesmeyer M, Bärthel E, Jandt K, Katenkamp K, Steenbeck J, Sappler A, Habrecht O, Gottschald D, Settimacher U. 18F-FDG PET of hepatocellular carcinoma on PET predicts microvascular tumor invasion in liver transplant patients. *Am J Transplant 2009; 9*: 592-600 [PMID: 19191771 DOI: 10.1111.j.1600-6143.2008.02516.x]

Kornberg A, Kipper B, Tannapfel A, Büchler P, Krause B, Witt U, Gottschald D, Friess H. Patients with non-[18F]fludeoxyglucose-avid advanced hepatocellular carcinoma on clinical staging may achieve long-term recurrence-free survival after liver transplantation. *Liver Transpl 2012; 18*: 53-61 [PMID: 21850692 DOI: 10.1002/lt.22416]

Lee SD, Kim SH, Kim YK, Kim C, Kim SK, Han SS, Park SJ. (18)F-FDG-PET/CT predicts early tumor recurrence in living donor liver transplantation for hepatocellular carcinoma. *Transpl Int 2013; 26*: 50-60 [PMID: 23106431 DOI: 10.1111/tci.2012.001572.x]

Detry O, Govaerts L, Deroyer I, Vandemeren M, Meurisse N, Malenga S, Baret N, Mbendi C, Lamproye A, Honore P, Meunier P, Delwaide J, Huntsin R. Prognostic value of (18)F-FDG-PET/CT in liver transplantation for hepatocarcinoma. *World J Gastroenterol* 2015; 21: 3049-3054 [PMID: 25780305 DOI: 10.3748/wjg.v21.i10.3049]

Hong G, Suh KS, Suh SW, Yoo T, Kim H, Park MS, Choi Y, Paeng JC, Yi NJ, Lee KW. Alpha-fetoprotein and (18)F-FDG positron emission tomography predict tumor recurrence better than Milan criteria in living donor liver transplantation. *J Hepatol 2016; 64*: 852-859 [PMID: 26653868 DOI: 10.1016/j.jhep.2015.11.031]

Hsu CC, Chen CL, Wang CC, Lin CC, Yong CC, Wang SH, Liu YW, Lin TL, Lee WF, Lin YH, Chan YC, Wu YJ, Eng HL, Cheng YF. Combination of FDG-PET and UCSF Criteria for Predicting HCC Recurrence After Living Donor Liver Transplantation. *Transplantation 2016; 100*: 1925-1932 [PMID: 27307534 DOI: 10.1097/TP.0000000000001297]

Lee SD, Lee B, Kim SH, Lee JO, Kim SK, Kim YK, Park SJ. Proposal of new expanded selection criteria using total tumor size and (18)F-fluorodeoxyglucose - positron emission tomography/computed tomography for living donor liver transplantation in patients with hepatocellular carcinoma: The National Cancer Center Korea criteria. *World J Transplant 2016; 6*: 411-422 [PMID: 27358787 DOI: 10.5596/wjt.v6.i2.411]

Kornberg A, Witt U, Schernhammer M, Kornberg J, Ceyhan GO, Mueller K, Friess H, Thrum K. Combining [18F]-FDG positron emission tomography with Up-to-seven criteria for selecting suitable liver transplant patients with advanced hepatocellular carcinoma. *Sci Rep 2017; 7*: 14176 [PMID: 29074966 DOI: 10.1038/s41598-017-14430-9]

Takada Y, Kaido T, Shirahe K, Nagano H, Egawa H, Sugawara Y, Taketomi A, Takahara T, Wakabayashi G, Nakanishi C, Kawagishi N, Kenjo A, Gotoh M, Toyoki Y, Hakamada K, Ohtsuka M, Miyazaki M, Takada T; LTx-PET study group of the Japanese Society of Hepato-Biliary-Pancreatic Surgery and the Japanese Liver Transplantation Society. Significance of preoperative fluorodeoxyglucose-positron emission tomography in prediction of tumor recurrence after liver transplantation for hepatocellular carcinoma patients: a Japanese multicenter study. *J Hepatobiliary Pancreat Sci 2017; 24*: 49-57 [PMID: 27806265 DOI: 10.1002/jhp.412]

Ye YF, Wang W, Wang T, Yu J, Geng L, Yu SF, Yan S, Zheng SS. Role of [18F] fludeoxyglucose positron emission tomography in the selection of liver transplantation candidates in patients with hepatocellular carcinoma. *Hepatobiliary Pancreat Dis Int 2017; 16*: 257-263 [PMID: 28603091 DOI: 10.1016/S1424-9343(16)30011-0]

Mazzalferro V, Regalia E, Doei R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A, Gemmari L. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. *N Engl J Med 1996; 334*: 693-699 [PMID: 8594428 DOI: 10.1056/nejm19960105.411]

Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. *Hepatology 2001; 33*: 1394-1403 [PMID: 11391528 DOI: 10.1002/152.4]

Song MJ, Baek SH, Yoo IeR, Park CH, Jung JW, Chun HJ, Choi BG, Lee HG, Choi JY, Yoon SK. Predictive value of 1'-fluorodeoxyglucose PET/CT for transarterial chemoembolization of hepatocellular carcinoma. *World J Gastroenterol 2012; 18*: 3215-3222 [PMID: 22783045 DOI: 10.3748/wjg.v18.i25.3215]

Song MJ, Baek SH, Lee SW, Song DS, Kim HY, Yoo IeR, Choi JI, Lee YJ, Chun HJ, Lee HG, Choi JY, Yoon SK. 18F-fluorodeoxyglucose PET/CT predicts tumor progression after transarterial chemoembolization in hepatocellular carcinoma. *Eur J Nucl Med Mol Imaging 2013; 40*: 865-873 [PMID: 23436073 DOI: 10.1007/s00259-013-2366-2]

Ma W, Jia J, Wang S, Bai W, Yi J, Bai M, Quan Z, Yin Z, Fan D, Wang J, Han G. The prognostic value of 18F-FDG PET/CT for hepatocellular carcinoma treated with transarterial chemoembolization (TACE). *Theranostics 2014; 4*: 736-744 [PMID: 24883123 DOI: 10.7150/thno.8725]

Kim MJ, Kim YS, Cho YH, Jang HY, Song JY, Lee SH, Jeong SW, Kim SG, Jung JY, Kim HS, Kim BS, Lee WH, Park JM, Lee JM, Lee MH, Choi DL. Use of (18)F-FDG PET to predict tumor progression and survival in patients with intermediate hepatocellular carcinoma treated by transarterial chemoembolization. *Korean J Intern Med 2015; 30*: 308-315 [PMID: 25905661 DOI: 10.3944/kjm.2015.30.3.308]
Kim BK, Kang WJ, Kim JK, Seong J, Park JY, Kim DY, Ahn SH, Lee DY, Lee KH, Lee JD, Han KH. 18F-fluorodeoxyglucose uptake on positron emission tomography as a prognostic predictor in locally advanced hepatocellular carcinoma. Cancer 2011; 117: 4779-4787 [PMID: 21490802 DOI: 10.1002/cncr.26999]

Huang WV, Kao CH, Huang WS, Chen CM, Chang LP, Lee MS, Chao HL, Chiu CH, Lo CH, Jen YM. 18F-FDG PET and combined 18F-FDG-contrast CT parameters as predictors of tumor control for hepatocellular carcinoma after stereotactic ablative radiotherapy. J Nucl Med 2013; 54: 1710-1716 [PMID: 23970365 DOI: 10.2967/jnumed.112.119379]

Rhee WJ, Hwang SH, Byun HK, Yun M, Han KH, Seong J. Risk stratification for locally advanced hepatocellular carcinoma using pretreatment alpha-fetoprotein and 18F-fluoro-2-deoxyglucose positron emission tomography. Liver Int 2017; 37: 592-599 [PMID: 27804192 DOI: 10.1111 liv.13297]

Kucuk ON, Soydal C, Araz M, Bilgic S, Ibis E. Prognostic importance of 18F- FDG uptake pattern of hepatocellular cancer patients who received SIRT. Clin Nucl Med 2013; 38: e283-e289 [PMID: 23313777 DOI: 10.1097/RLU.0b013e3182807171]

Sabet A, Ahmadzadehfar H, Bruhman J, Sabet A, Meyer C, Wasmuth JC, Pieper CC, Briersack HJ, Ezziddin S. Survival in patients with hepatocellular carcinoma treated with 90Y-microsphere radioembolization. Prediction by 18F-FDG PET. Nuklearmedizin 2014; 53: 39-45 [PMID: 24773754 DOI: 10.3413/Nukmed-0622-13-09]

Soydal C, Keskin O, Kucuk ON, Ozkan E, Bilgic S, Idilman R, Kir MK. Prognostic factors for prediction of survival of hepatocellular cancer patients after selective internal radiation therapy. Ann Nucl Med 2015; 29: 426-430 [PMID: 25782380 DOI: 10.1007/s12149-015-0962-x]

Aboueleich M, Naghavi AO, Ahmed KA, Venkat PS, Kim Y, Kim B, Choi J, Biebel B, Sweeney J, Anaya DA, Kim R, Malafi M, Frakes JM, Hoffe SE, El-Haddad G. Prognostic value of pre-treatment F-18-FDG PET-CT in patients with hepatocellular carcinoma undergoing radioembolization. World J Gastroenterol 2016; 22: 10406-10414 [PMID: 28058021 DOI: 10.3748/wjg.v22.i47.10406]

Jreige M, Mitsakis P, Van Der Gucht A, Pomonis A, Silva-Monteiro M, Gnesis S, Boubaker A, Nicol Lalande M, Duran R, Prior JO, Denys A, Schafer N. 18F-FDG PET/CT predicts survival after 90Y transarterial radioembolization in unsectable hepatocellular carcinoma. J Nucl Med Mol Imaging 2017; 44: 1215-1222 [PMID: 28233086 DOI: 10.2967/jnumed.116.176530]

Lee JH, Park JY, Kim DY, Ahn SH, Han KH, Seo HJ, Lee JD, Choi HJ. Prognostic value of 18F-FDG PET for hepatocellular carcinoma patients treated with sorafenib. Liver Int 2011; 31: 1144-1149 [PMID: 21441228 DOI: 10.1111/j.1640-5846.2011.05254.x]

Hyun SH, Eo JS, Lee JW, Choi JY, Lee KH, Na SJ, Hong IK, Oh JK, Chung YA, Song BI, Kim TS, Kim KS, Moon DH, Yun M. Prognostic value of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with Barcelona Clinic Liver Cancer stages 0 and A hepatocellular carcinomas: a multicenter retrospective cohort study. Eur J Nucl Med Mol Imaging 2016; 43: 1638-1645 [PMID: 26936852 DOI: 10.1007/s00259-016-3349-6]

Na SJ, Oh JK, Hwang SH, Park JY, Kim DY, Han KH, Seo HJ, Lee JD, Yun M. Prognostic Significance of 18F-FDG Uptake in Hepatocellular Carcinoma Treated with Transarterial Chemoembolization or Concurrent Chemoradiotherapy: A Multicenter Retrospective Cohort Study. J Nucl Med 2017; 58: 730-736 [PMID: 27789714 DOI: 10.2967/jnumed.116.180222]

Lee JW, Oh JK, Chung YA, Na SJ, Hyun SH, Hong IK, Eo JS, Song BI, Kim TS, Kim KS, Moon DH, Lee JD, Yun M. Prognostic Significance of 18F Uptake in Hepatocellular Carcinoma Treated with Transarterial Chemoembolization or Concurrent Chemoradiotherapy: A Multicenter Retrospective Cohort Study. J Nucl Med 2016; 57: 509-516 [PMID: 26742711 DOI: 10.2967/jnumed.115.167313]

Hyun SH, Eo JS, Song BI, Lee JW, Na SJ, Hong IK, Oh JK, Chung YA, Kim TS, Yun M. Preoperative prediction of microvascular invasion of hepatocellular carcinoma using 18F-FDG PET/CT: a multicenter retrospective cohort study. Eur J Nucl Med Mol Imaging 2018; 45: 720-726 [PMID: 29167923 DOI: 10.1007/s00259-017-3880-4]

Lee JW, Hwang SH, Kim DY, Han KH, Yun M. Prognostic Value of F-18 FDG Uptake of Portal Vein Tumor Thrombosis in Patients with Locally Advanced Hepatocellular Carcinoma. Clin Nucl Med 2017; 42: e35-e40 [PMID: 27775940 DOI: 10.1097/RLU.0000000000001422]

Toyosaka A, Okamoto E, Mitsuobu M, Oiyama T, Nakao N, Miura K. Intrahepatic metastases in hepatocellular carcinoma: evidence for spread via the portal vein as an effervescent vessel. Am J Gastroenterol 1996; 91: 1610-1615 [PMID: 8759671]

Addario L, Tritto G, Cavagliá E, Amoldio F, Giannelli E, Di Costanzo GG. Preserved liver function, portal thrombosis and absence of oesophageal varices are risk factors for metastasis of hepatocellular carcinoma. Dig Liver Dis 2011; 43: 319-324 [PMID: 20952262 DOI: 10.1016/j.dld.2010.09.003]

Larson SM, Erdi Y, Akhurst T, Mazumdar M, Macapinlac HA, Finn RD, Casilla C, Fazzari M, Srivastava N, Yeung HW, Humm JL, Guillem J, Downey R, Karpeh M, Cohen AE, Ginsberg R. Tumor Thrombosis and Absence of Oesophageal Varices Are Risk Factors for Metastasis of Hepatocellular Carcinoma. J Nucl Med 2014; 55: 99-104 [PMID: 24716469 DOI: 10.2967/jnumed.113.131847]

Im HJ, Braidshaw T, Solaiyappan M, Cho SY. Current Methods to Define Metabolic Tumor Volume in Positron Emission Tomography: Which One is Better? Eur J Nucl Med Mol Imaging 2018; 45: 2-15 [PMID: 29391907 DOI: 10.1007/s00259-017-0493-6]

Hyun SH, Choi JY, Kim K, Kim J, Shim YM, Um SW, Kim H, Lee KH, Kim BT. Volume-based parameters of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography improve outcome prediction in early-stage non-small cell lung cancer after surgical resection. Ann Surg 2013; 257: 364-370 [PMID: 22986069 DOI: 10.1097/SLA.0b013e318262a6ec]

Ryu IS, Kim JS, Roh JL, Lee JH, Cho KJ, Choi SH, Nam SY, Kim SY. Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis measured by 18F-FDG PET/CT in salivary gland carcinomas. J Nucl Med 2013; 54: 1032-1038 [PMID: 23670902 DOI: 10.2967/jnumed.112.116053]

Lee JW, Yun M, Cho A, Han KH, Kim DY, Lee SM, Lee JD. The predictive value of metabolic tumor
volume on FDG PET/CT for transarterial chemoembolization and transarterial chemotherapy infusion in hepatocellular carcinoma patients without extrahepatic metastasis. Ann Nucl Med 2015; 29: 400-408 [PMID: 25623647 DOI: 10.1007/s12149-015-0595-8].

91 Kim YJ, Paeng JC, Cheon GJ, Suh KS, Lee DS, Chung JK, Kang KW. Prediction of Posttransplantation Recurrence of Hepatocellular Carcinoma Using Metabolic and Volumetric Indices of 18F-FDG PET/CT. J Nucl Med 2016; 57: 1045-1051 [PMID: 26985057 DOI: 10.2967/jnumed.115.170076].

92 Hwang SH, Lee JW, Cho HJ, Kim KS, Choi GH, Yun M. Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis on Preoperative 18F-FDG PET/CT in Patients With Very Early and Early Hepatocellular Carcinoma. Clin Nucl Med 2017; 42: 34-39 [PMID: 27779590 DOI: 10.1097/RLU.0000000000001449].

93 Lee JW, Hwang SH, Kim HJ, Kim D, Cho A, Yun M. Volumetric parameters on FDG PET can predict early intrahepatic recurrence-free survival in patients with hepatocellular carcinoma after curative surgical resection. Eur J Nucl Med Mol Imaging 2017; 44: 1984-1994 [PMID: 28695236 DOI: 10.1007/s00259-017-3764-7].

94 Shimada M, Takenaka K, Gion T, Fujiwara Y, Kajiyama K, Maeda T, Shirabe K, Nishizaki T, Yanaka K, Sugimachi K. Prognosis of recurrent hepatocellular carcinoma: a 10-year survival experience in Japan. Gastroenterology 1996; 111: 720-726 [PMID: 8780576].

95 Poon RT, Fan ST, Ng RJ, Lo CM, Liu CL, Wong J. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer 2000; 89: 500-507 [PMID: 10931448].

96 Uchino K, Tateishi R, Shima S, Kanda M, Masuzaki R, Kondo Y, Goto T, Ornata M, Yoshida H, Koike K. Hepatocellular carcinoma with extrahepatic metastasis: clinical features and prognostic factors. Cancer 2013; 117: 4475-4483 [PMID: 21437894 DOI: 10.1002/ezra.25960].

97 Ochi H, Hirooka M, Hirooka A, Koizumi Y, Abe M, Sogabe I, Ishimaru Y, Furuya K, Miyagawa M, Kawasaki H, Michitaka K, Takada Y, Mochizuki T, Hiasa Y. 18F-FDG-PET/CT predicts the distribution of microsatellite lesions in hepatocellular carcinoma. Mol Clin Oncol 2014; 2: 798-804 [PMID: 25054048 DOI: 10.3892/ncmo.2014.322].

98 Park S, Kim TS, Kang SH, Kim HB, Park JW, Kim SK. 11C-acetate and 18F-fluorodeoxyglucose positron emission tomography/computed tomography dual imaging for the prediction of response and prognosis after transarterial chemotherapy. Medicine (Baltimore) 2018; 97: e12311 [PMID: 30212970 DOI: 10.1097/MD.00000000000012311].

99 Ahn SG, Jeon TJ, Lee SD, Kim SH, Cho HJ, Yun M, Park YN, Lee JD, Park SJ, Kim KS. A survival benefit of major hepatectomy for hepatocellular carcinoma identified by preoperative [18F] fluorodeoxyglucose positron emission tomography in patients with well-preserved hepatic function. Eur J Surg Oncol 2013; 39: 964-973 [PMID: 23859893 DOI: 10.1016/j.ejso.2013.06.019].

100 Kim JW, Seong J, Yun M, Lee HJ, Yoon HI, Cho HJ, Han KH. Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose in predicting treatment response in unresectable hepatocellular carcinoma patients treated with external beam radiotherapy. Int J Radiat Oncol Biol Phys 2012; 82: 1172-1178 [PMID: 21570203 DOI: 10.1016/j.ijrobp.2010.11.076].

101 Choi SH, Chang JS, Jeong YH, Lee Y, Yun M, Seong J. FDG-PET predicts outcomes of treated bone metastases following palliative radiotherapy in patients with hepatocellular carcinoma. Liver Int 2014; 34: 1118-1125 [PMID: 24528941 DOI: 10.1111/liv.12487].

102 Jo YI, Son SH, Kim M, Sung SY, Won YK, Kang HJ, Lee SJ, Chung YA, Oh JK, Kay CS. Prognostic value of pretreatment (18)F-FDG-PET/CT in radiotherapy for patients with hepatocellular carcinoma. Radiat Oncol 2015; 33: 179-187 [PMID: 26848301 DOI: 10.3857/roj.2015.33.3.179].

103 Aerts HJ, Velazquez ER, Leijenaar RT, Parmar C, Grossmann P, Carvalho S, Bluemink J, Monshouwer R, Kaanders JH, Lambin P. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun 2014; 5: 4006 [PMID: 24892406 DOI: 10.1038/ncomms4006].

104 Lambin P, Rios-Velazquez E, Leijenaar R, Carvalho S, van Stiphout RG, Granton P, Zegers CM, Gilles R, Boelard R, Dekker A, Aerts HJ. Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer 2012; 48: 441-446 [PMID: 22257792 DOI: 10.1016/j.ejca.2011.10.036].

105 Lee JW, Lee SM. Radiomics in Oncological PET/CT: Clinical Applications. Nucl Med Mol Imaging 2018; 52: 170-189 [PMID: 29942396 DOI: 10.1007/s12139-017-0500-3].

106 Hatt M, Majdoub M, Vallières M, Tixier F, Le Rest CC, Groheux D, Hindou E, Martineau A, Pradier O, Hustinx R, Perdrisot R, Guillevin R, El Naqa I, Visvikis D. 18F-FDG PET uptake characterization through texture analysis: investigating the complementary nature of heterogeneity and functional tumor volume in a multi-cancer site patient cohort. J Nucl Med 2015; 56: 38-44 [PMID: 25085280 DOI: 10.2967/jnumed.114.144055].

107 Blanck Durand P, Van Der Gucht A, Iveige M, Niced-Lalonde M, Silva-Monteiro M, Prior JO, Denys A, Depeursinge A, Schaefer N. Signature of survival: a [18F]-FDG PET based whole-liver radiomic analysis predicts survival after 18F-TARE for hepatocellular carcinoma. Oncotarget 2017; 9: 4549-4558 [PMID: 29435123 DOI: 10.18632/oncotarget.23423].

108 Choi H. Deep Learning in Nuclear Medicine and Molecular Imaging: Current Perspectives and Future Directions. Nucl Med Mol Imaging 2018; 52: 109-118 [PMID: 29662559 DOI: 10.1007/s12139-017-0504-7].

P-Reviewer: Tsoufas G
S-Editor: Ma RY L-Editor: A E-Editor: Huang Y
